Get all your news in one place.
100's of premium titles.
One app.
Start reading
The Guardian - UK
The Guardian - UK
Business
Julia Kollewe

AstraZeneca’s Evusheld Covid-prevention drug gets UK approval

Staff at AstraZeneca’s Discovery Centre in Cambridge, England.
Staff at AstraZeneca’s Discovery Centre in Cambridge, England. Photograph: Alecsandra Dragoi/The Guardian

AstraZeneca has received UK regulatory approval for its long-acting Covid-19 antibody treatment Evusheld in a boost to its coronavirus portfolio, as the British-Swedish drugmaker targets greater drug development success at its new £1bn research lab in Cambridge.

Aimed at preventing Covid infections in people with poor immune systems who cannot be vaccinated, Evusheld is already approved in the US, France and other countries, and the US government has ordered 1.7m doses.

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.